Loading
CI
CohBar, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by GREENWOOD DAVID, was filed 02 Nov 2021.
CohBar, Inc.: what insiders have been doing
This page follows insider dealings at CohBar, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. No insider at CohBar, Inc. has published a filing in the past twelve months. The most recent one dates from 3 August 2022.
Over the whole record (from 2016), the tally stands at 14 purchases and 24 sales.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
79
Thresholds
n/a
Buy Volume
€116,739
14 ops. · all time
Sell Volume
€275,049
24 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$10.5M
Last declaration on 3 August 2022
Declarations79 total
26,203 shares@ US$0.1488100.0% of flowCommon StockSEC:0001213900-22-044290:0
131,017 shares@ US$0.148849.8% of flowCommon StockSEC:0001213900-22-044289:0
20,000 sharesCommon StockSEC:0001213900-21-055982:0
Canonical exit: 30 Jan 2022 (T+90)
13,889 sharesCommon StockSEC:0001213900-21-055981:0
Canonical exit: 30 Jan 2022 (T+90)
167,000 shares@ US$0.5759100.0% of flowCommon StockSEC:0001213900-21-055664:0
Canonical exit: 26 Jan 2022 (T+90)
20,000 shares@ US$1.1250.2% of flowCommon StockSEC:0001213900-21-043795:0
Canonical exit: 16 Nov 2021 (T+90)
4,000 shares0Common StockSEC:0001213900-21-043644:1
4,000 shares0Common StockSEC:0001213900-21-043644:0
10,000 shares@ US$2.016.5% of flowCommon StockSEC:0001213900-21-042466:1
10,000 shares@ US$0.73100.0% of flowCommon StockSEC:0001213900-21-042466:0
10,000 shares@ US$1.906.0% of flowCommon StockSEC:0001213900-21-010340:1
10,000 shares@ US$0.732.3% of flowCommon StockSEC:0001213900-21-010340:0
99,861 sharesCommon StockSEC:0001213900-20-044063:0
Canonical exit: 18 Mar 2021 (T+90)
7,490 sharesCommon StockSEC:0001213900-20-044061:0
Canonical exit: 18 Mar 2021 (T+90)
11,000 shares@ US$1.029.8% of flowCommon StockSEC:0001213900-20-025331:0
Canonical exit: 2 Dec 2020 (T+90)
6,000 shares@ US$1.005.2% of flowCommon StockSEC:0001213900-20-025152:0
Canonical exit: 1 Dec 2020 (T+90)
8,196 sharesCommon StockSEC:0001213900-20-024781:0
Canonical exit: 26 Nov 2020 (T+90)
20,000 sharesCommon StockSEC:0001213900-20-024782:0
Canonical exit: 26 Nov 2020 (T+90)
8,169 sharesCommon StockSEC:0001213900-20-024787:0
Canonical exit: 26 Nov 2020 (T+90)
204,918 sharesCommon StockSEC:0001213900-20-024785:0
Canonical exit: 26 Nov 2020 (T+90)
10,000 shares@ US$0.732.6% of flowCommon StockSEC:0001213900-20-021161:0
10,000 shares@ US$1.906.8% of flowCommon StockSEC:0001213900-20-021161:1
10,000 shares@ US$0.732.7% of flowCommon StockSEC:0001213900-20-015186:0
10,000 shares@ US$2.418.8% of flowCommon StockSEC:0001213900-20-015186:1
10,000 shares@ US$0.732.8% of flowCommon StockSEC:0001213900-20-012811:0
25 of 79 declarations
About CohBar, Inc.
CohBar, Inc. is a U.S.-listed biopharmaceutical company that historically traded on the NASDAQ under the ticker CWBR and was based in Menlo Park, California, United States. Founded in 2007, the company was built around a highly specialized scientific thesis: using mitochondrial-derived peptides and mitochondria-based biology to discover potential therapies for chronic, inflammatory, metabolic, and age-related diseases. In that sense, CohBar belongs to the small-cap biotech universe where valuation is driven primarily by the strength of the platform, the quality of the intellectual property portfolio, and the ability to advance programs toward clinical proof of concept, rather than by current revenue generation.
CohBar’s core business model has centered on a discovery engine known as MITO+, designed to identify and optimize peptide analogs derived from the mitochondrial genome. This platform-oriented approach positioned the company as a research-driven developer of novel therapeutics, with a pipeline that historically included preclinical and early-stage candidates rather than commercial products. For investors, that matters because the company’s economics have typically reflected the profile of a development-stage biotech: heavy R&D dependence, recurring capital needs, dilution risk, and a binary sensitivity to clinical and strategic milestones.
Read moreShow less
The most important recent corporate event was CohBar’s 2023 merger agreement with Morphogenesis. Public filings and company releases indicated that the combined entity was expected to operate as TuHURA Biosciences and pursue a NASDAQ listing, signaling a major strategic pivot away from CohBar’s standalone legacy structure. Those disclosures also showed that CohBar had suspended development activities, underscoring that the company was no longer functioning as a conventional independent biotech with an active late-stage pipeline. Instead, it was transitioning into a transaction-driven situation where merger execution, financing structure, and post-deal strategic direction became the key investment variables.
From a competitive standpoint, CohBar was a niche science company rather than a broad-based pharmaceutical competitor. Its differentiated angle was mitochondrial peptide biology, a relatively uncommon therapeutic approach compared with mainstream small molecules, antibodies, or RNA-based platforms. That differentiation could create optionality, but it also implied substantial scientific and execution risk. Geographically, the company’s principal operations were centered in California, while its investor-facing identity remained clearly U.S.-listed and NASDAQ-oriented.
For French, Belgian, and Swiss investors, the stock should be viewed as a high-risk U.S. micro-cap biotech story with a legacy platform, limited operating maturity, and major corporate-action sensitivity. In practical terms, the key items to monitor are SEC filings, insider transactions reported on Form 4, and any updates on merger completion, capital structure, or post-merger listing status.
